Our study takes the first step along this road by building a model, based on known mechanisms from the literature, to describe the changes in protein expression and proliferation of an E2-dependent, asynchronous population of ER+ MCF-7 breast cancer cells in response to various clinically relevant therapies over a time period of one week. Here, ESR1 is linked to breast carcinoma.